EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

Farnam Barati Sedeh, Thorunn Elísabet Michaelsdóttir, Mattias Arvid Simon Henning, Gregor Borut Ernst Jemec, Kristina Sophie Ibler

Acta Dermato-Venereologica · 2023

DOI: 10.2340/actadv.v103.4536 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Acta Dermato-Venereologica, 2023. Verfasst von Farnam Barati Sedeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Zealand University Hospital, Roskilde, Denmark. farb@regionsjaelland.dk. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane library. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as ≥ 50% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alopecia areata defined as a SALT score ≥ 50, oral deuruxolitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are required to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsHumansAlopeciaPyrazolesAzetidinesPurinesSulfonamides

Substanzen

Janus Kinase InhibitorsPyrazolesbaricitinibAzetidinesPurinesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, Zealand University Hospital, Roskilde, Denmark. farb@regionsjaelland.dk.
  • Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.

Zitieren

APA

Barati Sedeh, F., Michaelsdóttir, T. E., Henning, M. A. S., Jemec, G. B. E., & Ibler, K. S. (2023). Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v103.4536

Vancouver

Barati Sedeh F, Michaelsdóttir TE, Henning MAS, Jemec GBE, Ibler KS. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica. 2023. doi:10.2340/actadv.v103.4536

BibTeX
@article{BaratiSedeh2023,
  author = {Barati Sedeh, Farnam and Michaelsdóttir, Thorunn Elísabet and Henning, Mattias Arvid Simon and Jemec, Gregor Borut Ernst and Ibler, Kristina Sophie},
  title = {Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis},
  journal = {Acta Dermato-Venereologica},
  year = {2023},
  doi = {10.2340/actadv.v103.4536}
}
Kostenlos starten →